Case report: Successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novel CARD14 mutation

Michal Niedzwiedz*, Joanna Narbutt, Aleksandra Siekierko, Malgorzata Skibinska, Bartlomiej Kwiek, Dorota Sobolewska-Sztychny, Magdalena Ciazynska, Katarzyna Poznanska-Kurowska, Antoni Gostynski, Aleksandra Lesiak

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

CARD14 (caspase activation and recruitment domain) mutations have been associated with psoriasis vulgaris, psoriatic arthritis, generalized and palmoplantar pustular psoriasis, pityriasis rubra pilaris, and atopic dermatitis. We present a pediatric patient with a novel CARD14: c.394A > T/- (Ile123Phe) mutation, diagnosed with CARD14-associated papulosquamous eruption (CAPE), who was successfully treated with biological treatment.
Original languageEnglish
Article number1360248
Number of pages8
JournalFrontiers in medicine
Volume11
DOIs
Publication statusPublished - 5 Feb 2024

Keywords

  • CARD14
  • CAPE
  • biologics
  • adalimumab
  • ustekinumab
  • case report
  • CARD14: c.394A > T/- (Ile123Phe)
  • CARD14-associated papulosquamous eruption
  • PSORIASIS

Cite this